Clinical Report: ODs in Clinical Trials: Where Do You Fit?
Overview
This report discusses the evolving role of optometrists (ODs) in clinical trials, highlighting their increasing involvement in various stages of research.
Background
Clinical trials are critical in shaping modern eye care, influencing FDA approvals, standards of care, and clinical practice guidelines. The involvement of optometrists in these trials is growing.
Data Highlights
No numerical data was provided in the source material.
Key Findings
- Optometrists are increasingly involved in clinical trials as primary or subinvestigators.
- Clinical trials can be categorized into five groups: treatment, prevention, screening, diagnostic, and quality-of-life trials.
- Clinical trials are conducted in four phases: safety (Phase 1), early efficacy (Phase 2), large validation (Phase 3), and postmarket surveillance (Phase 4).
- Patients may participate in trials for access to innovative therapies, altruism, and financial support, but may also face barriers such as misconceptions and anxiety.
- Ethical principles guiding clinical research include informed consent, risk discussion, and voluntary participation.
Clinical Implications
Optometrists should familiarize themselves with the clinical trial process to enhance their roles in research and improve patient care. Understanding the ethical considerations and operational aspects of trials can help ODs navigate their involvement effectively.
Conclusion
The participation of optometrists in clinical trials is vital for advancing eye care practices. By understanding the structure and ethical considerations of these trials, ODs can contribute to and benefit from ongoing research efforts.
Related Resources & Content
- Mohammad Rafieetary, OD, FAAO, FORS, Roya Attar, OD, MBA, DHA, FAAO, FORS, 2026 AOA At Optometry's Meeting -- ODs in Clinical Trials: Where Do You Fit?
- Ophthalmology Management — Boost Your Practice With Clinical Trials
- retinal physician — Home OCT and Modeling May Reduce Trial Sizes
- Retinal Physician — RETINA CONVERSATIONS: A Conversation With Namrata Saroj, OD
- The Journal of Clinical Endocrinology & Metabolism — Effectiveness and Safety of Osilodrostat in Nonpituitary Cushing Syndrome: Insights from Real-World Data
- Boost Your Practice With Clinical Trials
- Home OCT and Modeling May Reduce Trial Sizes
- RETINA CONVERSATIONS: A Conversation With Namrata Saroj, OD
- ICH Harmonised Guideline for Good Clinical Practice E6(R3) - Step 4 Final
- Conducting Clinical Trials With Decentralized Elements Guidance for Industry, Investigators, and Other Interested Parties
- Primary Open-Angle Glaucoma Preferred Practice Pattern® - Ophthalmology
- Diabetic Retinopathy Preferred Practice Pattern® - Ophthalmology
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 - PMC
- Diversified Segmental Defocus Optimization Lenses With and Without Atropine for Myopia Prevention: A Randomized Clinical Trial | Trials | JAMA Ophthalmology | JAMA Network
- Assessment of the Effectiveness, Tolerability, and Safety of the Preservative-Free Fixed Combination of Timolol, Dorzolamide, and Brimonidine Compared to Separate Therapies in Patients with Glaucoma, a Randomized Controlled Trial - PubMed
- Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - PubMed
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.


